ClinicalTrials.gg

Program

pembrolizumab

Also written as “Pembrolizumab”, “Pembrolizumab 200 mg” and “NGM707 plus pembrolizumab (KEYTRUDA®)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Squamous Cell Carcinoma of Head and Neck · Stomach Neoplasms · Urinary Bladder Neoplasms, led by 8 companies.

Furthest: phase 4, since Oct 19, 2018148 company-led studies, 27 open or runningNext primary completion: Nov 20, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck13824 open or runningphase 4since Oct 19, 2018Feb 10, 2011Nov 20, 2026phase 3 · NCT04634877
Novartis30 open or runningphase 2since May 15, 2019Dec 12, 2013none ahead
PDS Biotechnology20 open or runningphase 3since Jan 14, 2025Feb 5, 2020none ahead
ago-research-gmbh11 open or runningphase 2since May 11, 2023May 11, 2023Oct 30, 2027phase 2 · NCT05903833
evernov-medicines-zhuhai-hengqin-co-ltd10 open or runningphase 2since Dec 29, 2020Dec 29, 2020none ahead
mediclinic-middle-east10 open or runningphase 2since Mar 14, 2019Mar 14, 2019none ahead
NovoCure11 open or runningphase 3since Aug 13, 2024Aug 13, 2024Apr 2029phase 3 · NCT06556563
tiumbio-co-ltd11 open or runningphase 2since Feb 20, 2023Feb 20, 2023Dec 2026phase 2 · NCT05784688

Also a collaborator on its studies: Pfizer, Eisai, Astellas Pharma, novotech-australia-pty-limited and medidata-solutions.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 50 studies since Dec 13, 2018.

  1. Oct 28, 2021Phase 3 study in Ovarian NeoplasmsMerck · NCT05116189 · 643 enrolled · United States, Australia, Belgium and more
  2. Dec 20, 2021Phase 3 study in Endometrial NeoplasmsMerck · NCT05173987 · 280 enrolled · United States, Australia, Belgium and more
  3. Feb 4, 2022Phase 3 study in Colorectal NeoplasmsMerck · NCT05239741 · 100 enrolled · China
  4. Feb 20, 2023tiumbio-co-ltd's first study: phase 2 study in Biliary Tract NeoplasmsNew to tiumbio-co-ltdtiumbio-co-ltd · NCT05784688 · 140 planned · United States, Korea, Republic of
  5. May 11, 2023ago-research-gmbh's first study: phase 2 study in Vulvar NeoplasmsNew to ago-research-gmbhago-research-gmbh · NCT05903833 · 42 planned · Germany
  6. Oct 19, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungMerck · NCT06099782 · 147 enrolled · United States, Argentina, Australia and more
  7. Aug 13, 2024NovoCure's first study: phase 3 study in GlioblastomaNew to NovoCureNovoCure · NCT06556563 · 741 enrolled · United States, Canada, Czechia and more
  8. Jan 14, 2025Phase 3 study in Head and Neck NeoplasmsPDS Biotechnology · NCT06790966 · 12 enrolled · United States
  9. Dec 11, 2025Phase 2 study in NeoplasmsMerck · NCT07302347 · 20 planned · Japan
  10. Aug 28, 2026Phase 4 study in NeoplasmsMerck · NCT07801027 · 150 planned
  11. Sep 28, 2026Phase 3 study terminatedStudy stoppedNCT03833167 · “The study stopped due to futility”
  12. Sep 28, 2026Phase 3 study terminatedStudy stoppedNCT03834493 · “The study stopped due to futility”
  13. Sep 28, 2026Phase 3 study terminatedStudy stoppedNCT04191096 · “The study stopped due to futility”
  14. Oct 2, 2026Primary completion moved from 2026-11-06 to 2027-02-12Date moved laterphase 2 · +3 months · NCT03407144

Ahead

  1. Nov 20, 2026Primary completion: phase 3 study in Endometrial NeoplasmsMerck · NCT04634877
  2. Dec 2026Primary completion: phase 2 study in Biliary Tract Neoplasmstiumbio-co-ltd · NCT05784688
  3. Jan 31, 2027Primary completion: phase 3 study in Urinary Bladder NeoplasmsMerck · NCT04241185
  4. May 5, 2027Primary completion: phase 3 study in Lung NeoplasmsMerck · NCT04380636

TargetBeta

PDCD1 →read by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

The newest 60 of 148 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07801027Neoplasms4Not yet recruitingMerckJan 31, 2030150
NCT07302347Neoplasms · Japan2RecruitingMerckMar 30, 202920
NCT06790966Head and Neck Neoplasms · United States3TerminatedPDS BiotechnologyAug 25, 202612
NCT06556563Glioblastoma · United States, Canada, Czechia and more3Active, not recruitingNovoCureApr 2029741
NCT06099782Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more2Active, not recruitingMerckApr 9, 2025147
NCT05903833Vulvar Neoplasms · Germany2Recruitingago-research-gmbhOct 30, 202742
NCT05784688Biliary Tract Neoplasms · United States, Korea, Republic of2Recruitingtiumbio-co-ltdDec 2026140
NCT05239741Colorectal Neoplasms · China3Active, not recruitingMerckSep 19, 2028100
NCT05173987Endometrial Neoplasms · United States, Australia, Belgium and more3Active, not recruitingMerckMay 27, 2027280
NCT05116189Ovarian Neoplasms · United States, Australia, Belgium and more3Active, not recruitingMerckMar 5, 2025643
NCT05008224Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Australia, Canada and more2CompletedMerckOct 11, 2023146
NCT04956692Carcinoma, Non-Small-Cell Lung · United States, Brazil, France and more3CompletedMerckApr 4, 2023531
NCT04934722Parkinson Disease 4, Autosomal Dominant Lewy Body · China3CompletedMerckOct 31, 2022186
NCT04924062Parkinson Disease 4, Autosomal Dominant Lewy Body · China3CompletedMerckDec 15, 2022158
NCT04907227Prostatic Neoplasms · China3TerminatedMerckAug 3, 202281
NCT04895358Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingMerckApr 24, 2026342
NCT04882241Stomach Neoplasms · China3CompletedMerckFeb 16, 2024120
NCT04875195Hodgkin Disease · United States, Brazil, Canada and more2CompletedMerckDec 14, 202366
NCT04865289Endometrial Neoplasms · China3CompletedMerckOct 2, 2023130
NCT04859582Stomach Neoplasms · China3WithdrawnMerckNov 29, 20240
NCT04776148Colorectal Neoplasms · United States, Argentina, Australia and more3CompletedMerckSep 27, 2024563
NCT04704219Carcinoma, Renal Cell · United States, Australia, Canada and more2CompletedMerckJan 27, 2025160
NCT04700124Urinary Bladder Neoplasms · United States, Argentina, Australia and more3Active, not recruitingMerckOct 27, 2025808
NCT04699643Advanced Solid Tumors · China2UNKNOWNevernov-medicines-zhuhai-hengqin-co-ltdJun 202380
NCT04662710Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Argentina, Australia and more3CompletedMerckOct 29, 2024895
NCT04634877Endometrial Neoplasms · United States, Argentina, Austria and more3Active, not recruitingMerckNov 20, 2026990
NCT04624204Small Cell Lung Carcinoma · United States, Australia, Belgium and more3Active, not recruitingMerckOct 28, 2027672
NCT04489888Squamous Cell Carcinoma of Head and Neck · United States, Argentina, Australia and more4CompletedMerckFeb 20, 2023101
NCT04428151Squamous Cell Carcinoma of Head and Neck · United States, Australia, Brazil and more2CompletedMerckMay 31, 2024408
NCT04380636Lung Neoplasms · United States, Argentina, Canada and more3Active, not recruitingMerckMay 5, 2027870
NCT04317066Lymphoma, B-Cell · Japan1CompletedMerckApr 11, 20247
NCT04260126Head and Neck Neoplasms · United States, Ireland, Puerto Rico and more2CompletedPDS BiotechnologyMay 14, 202595
NCT04246177Carcinoma, Hepatocellular · United States, Australia, Brazil and more3TerminatedMerckAug 19, 2025480
NCT04241185Urinary Bladder Neoplasms · United States, Australia, Chile and more3Active, not recruitingMerckJan 31, 2027520
NCT04221945Uterine Cervical Neoplasms · United States, Australia, Austria and more3CompletedMerckJan 7, 20251,060
NCT04210115Esophageal Squamous Cell Carcinoma · United States, Argentina, Belgium and more3CompletedMerckJan 21, 2026703
NCT04191096Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Australia, Austria and more3TerminatedMerckOct 31, 20221,251
NCT04153565Mesothelioma · Japan1CompletedMerckSep 21, 202219
NCT04123366Solid Tumors · United States, Argentina, Australia and more2CompletedMerckJun 8, 2026333
NCT04003636Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Argentina, Australia and more3CompletedMerckDec 15, 20221,069
NCT03976375Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3CompletedMerckAug 11, 2023422
NCT03968419Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more2TerminatedNovartisApr 20, 202288
NCT03950674Carcinoma, Non-Small-Cell Lung · Japan3CompletedMerckMay 20, 201940
NCT03933449Esophageal Neoplasms · China3CompletedMerckFeb 13, 2019123
NCT03924895Urinary Bladder Neoplasms · United States, Argentina, Australia and more3Active, not recruitingMerckJun 6, 2025595
NCT03924869Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3TerminatedMerckJun 11, 2024448
NCT03924856Urinary Bladder Neoplasms · United States, Australia, Belgium and more3CompletedMerckJan 26, 2026907
NCT03884101Endometrial Neoplasms · United States, Argentina, Australia and more3CompletedMerckOct 2, 2023842
NCT03881111Esophageal Neoplasms · China3WithdrawnMerckMay 11, 20210
NCT03879174Breast Cancer Female · United Arab Emirates2UNKNOWNmediclinic-middle-eastAug 1, 202225
NCT03875092Carcinoma, Non-Small-Cell Lung · China3CompletedMerckSep 30, 2020125
NCT03867084Carcinoma, Hepatocellular · United States, Argentina, Australia and more3CompletedMerckMar 20, 2025959
NCT03850444Carcinoma, Non-Small-Cell Lung3CompletedMerckSep 4, 2018262
NCT03834519Prostatic Neoplasms · United States, Argentina, Australia and more3CompletedMerckMar 14, 2022793
NCT03834506Prostatic Neoplasms · United States, Argentina, Australia and more3CompletedMerckJun 20, 20221,030
NCT03834493Prostatic Neoplasms · United States, Argentina, Australia and more3TerminatedMerckDec 12, 20221,244
NCT03833167Carcinoma, Squamous Cell · United States, Argentina, Australia and more3TerminatedMerckJun 28, 2024450
NCT03797326Triple Negative Breast Neoplasms · United States, Argentina, Australia and more2CompletedMerckOct 28, 2024611
NCT03783078Carcinoma, Merkel Cell · United States, Australia, Canada and more3CompletedMerckFeb 15, 202255
NCT03776136Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Australia, Canada and more2CompletedMerckOct 11, 2023103

How it is read

Names in the registry

  • “Pembrolizumab”, 124 entries
  • “pembrolizumab”, 29 entries
  • “Pembrolizumab 200 mg”, 7 entries
  • “NGM707 plus pembrolizumab (KEYTRUDA®)”, 4 entries
  • “GV20-0251 and Pembrolizumab [KEYTRUDA®]”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.